BiotechTube

SUNPG1622 I dose + Placebo dose

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

Conditions

Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

Trial Timeline

Nov 6, 2017 → Sep 3, 2019

NCT ID
NCT02980705

About SUNPG1622 I dose + Placebo dose

SUNPG1622 I dose + Placebo dose is a phase 2 stage product being developed by Sun Pharmaceutical for Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02980705. Target conditions include Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02980705Phase 2Terminated

Competing Products

20 competing products in Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
mirabegron + solifenacinAstellas PharmaApproved
85
CDP870Astellas PharmaPhase 3
77
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Solifenacin succinateAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85